These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 21497044)

  • 1. Von Willebrand factor for predicting bleeding and mortality real deal or another failed biomarker?
    Serebruany VL
    J Am Coll Cardiol; 2011 Jun; 57(25):2505-6. PubMed ID: 21497044
    [No Abstract]   [Full Text] [Related]  

  • 2. Thrombogenesis in lone atrial fibrillation: a role for soluble P-selectin?
    Montoro-García S; Marín F; Lip GY
    Europace; 2011 Jan; 13(1):3-4. PubMed ID: 20974759
    [No Abstract]   [Full Text] [Related]  

  • 3. A study of blood soluble P-selectin, fibrinogen, and von Willebrand factor levels in idiopathic and lone atrial fibrillation.
    Fu R; Wu S; Wu P; Qiu J
    Europace; 2011 Jan; 13(1):31-6. PubMed ID: 20852292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. von Willebrand activation factor as a marker of mortality, cardiovascular events, and bleeding complications in patients treated with oral anticoagulants.
    Lind M; Johansson L; Nilsson TK; Jansson JH; Hollestelle MJ
    Thromb Res; 2015 Nov; 136(5):878-82. PubMed ID: 26364970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prothrombotic markers in atrial fibrillation: what is new?
    Al-Saady NM; Sopher M
    Eur Heart J; 2001 Sep; 22(18):1635-9. PubMed ID: 11511115
    [No Abstract]   [Full Text] [Related]  

  • 6. Subclinical atherosclerotic endothelial damage as predictor for bleeding in anticoagulated atrial fibrillation patients.
    Hernández-Romero D; Marín F; Roldán V; Lip GY
    J Intern Med; 2012 Oct; 272(4):409. PubMed ID: 22702474
    [No Abstract]   [Full Text] [Related]  

  • 7. Performance of the HEMORR 2 HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in nonwarfarin anticoagulated atrial fibrillation patients.
    Apostolakis S; Lane DA; Guo Y; Buller H; Lip GY
    J Am Coll Cardiol; 2013 Jan; 61(3):386-7. PubMed ID: 23246385
    [No Abstract]   [Full Text] [Related]  

  • 8. Bleeding risk on warfarin among elderly patients with atrial fibrillation.
    Cowan A; Hylek EM
    J Am Coll Cardiol; 2010 Mar; 55(9):932; author reply 932-3. PubMed ID: 20185052
    [No Abstract]   [Full Text] [Related]  

  • 9. Alterations of von Willebrand factor and ristocetin cofactor activity during atrial fibrillation.
    Kalyoncu U; Dizdar O; Erkan Duman A; Karadag O; Tufan A; Yucel O; Tayfur O; Sen D; Ulger Z; Kepez A; Kocabas U; Haznedaroglu I
    Clin Appl Thromb Hemost; 2009 Feb; 15(1):103-8. PubMed ID: 18160605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting the risk of bleeding in patients taking warfarin.
    Ebell MH
    Am Fam Physician; 2010 Mar; 81(6):780. PubMed ID: 20229978
    [No Abstract]   [Full Text] [Related]  

  • 11. Stroke prevention versus bleeding risk in atrial fibrillation: a clinical dilemma.
    Hohnloser SH
    J Am Coll Cardiol; 2011 Jan; 57(2):181-3. PubMed ID: 21111556
    [No Abstract]   [Full Text] [Related]  

  • 12. Bleeding rates in elderly patients on vitamin K antagonist therapy for nonvalvular atrial fibrillation.
    Tay KH; Lip GY; Lane DA
    Blood Coagul Fibrinolysis; 2009 Jul; 20(5):392-3. PubMed ID: 19542940
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of therapeutic INR on activated clotting times, heparin dosage, and bleeding risk during ablation of atrial fibrillation.
    Gautam S; John RM; Stevenson WG; Jain R; Epstein LM; Tedrow U; Koplan BA; McClennen S; Michaud GF
    J Cardiovasc Electrophysiol; 2011 Mar; 22(3):248-54. PubMed ID: 20812929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired flow mediated dilatation as evidence of endothelial dysfunction in chronic atrial fibrillation: relationship to plasma von Willebrand factor and soluble E-selectin levels.
    Freestone B; Chong AY; Nuttall S; Lip GY
    Thromb Res; 2008; 122(1):85-90. PubMed ID: 17996280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atrial fibrillation and dabigatran: has the time come to use new anticoagulants?
    Escobar C; Barrios V; Jimenez D
    Cardiovasc Ther; 2010 Oct; 28(5):295-301. PubMed ID: 20718760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bleeding problems of a patient with hypothyroidism].
    Paul R
    Duodecim; 2002; 118(13):1361-3. PubMed ID: 12239881
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Hansen ML; Sørensen R; Clausen MT; Fog-Petersen ML; Raunsø J; Gadsbøll N; Gislason GH; Folke F; Andersen SS; Schramm TK; Abildstrøm SZ; Poulsen HE; Køber L; Torp-Pedersen C
    Arch Intern Med; 2010 Sep; 170(16):1433-41. PubMed ID: 20837828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [INR self monitoring: large study shows no prognostic value].
    MMW Fortschr Med; 2008 Nov; 150(47):14. PubMed ID: 19186483
    [No Abstract]   [Full Text] [Related]  

  • 19. [Changes of endothelial function indices and their relation to platelet activation in idiopathic atrial fibrillation].
    Fu RB; Wu PS; Wu SL; Qiu J
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Apr; 30(4):771-3. PubMed ID: 20423847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.
    DiMarco JP; Flaker G; Waldo AL; Corley SD; Greene HL; Safford RE; Rosenfeld LE; Mitrani G; Nemeth M;
    Am Heart J; 2005 Apr; 149(4):650-6. PubMed ID: 15990748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.